Restoration of t cell substes of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells An in vitro study

Restoration of t cell substes of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells : An in vitro study

Copyright © 2015. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 163(2016) vom: 15. Feb., Seite 34-41
1. Verfasser: Montanucci, Pia (VerfasserIn)
Weitere Verfasser: Alunno, Alessia, Basta, Giuseppe, Bistoni, Onelia, Pescara, Teresa, Caterbi, Sara, Pennoni, Ilaria, Bini, Vittorio, Gerli, Roberto, Calafiore, Riccardo
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2016
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Adult mesenchymal stem cell HLAG-5 Immunomodulation Microencapsulation Proliferation inhibition Type 1 diabetes mellitus Antiviral Agents Capsules mehr... FOXP3 protein, human Forkhead Transcription Factors HLA-G Antigens IDO1 protein, human IL10 protein, human IL17A protein, human IL2 protein, human IL6 protein, human Indoleamine-Pyrrole 2,3,-Dioxygenase Interleukin-17 Interleukin-2 Interleukin-6 Interleukins TNF protein, human Transforming Growth Factor beta Tumor Necrosis Factor-alpha Interleukin-10 130068-27-8 Interferon-gamma 82115-62-6 NOS2 protein, human EC 1.14.13.39 Nitric Oxide Synthase Type II Hypoxanthine Phosphoribosyltransferase EC 2.4.2.8 Interleukin-21 MKM3CA6LT1
LEADER 01000caa a22002652c 4500
001 NLM255682921
003 DE-627
005 20250219113806.0
007 cr uuu---uuuuu
008 231224s2016 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2015.12.002  |2 doi 
028 5 2 |a pubmed25n0852.xml 
035 |a (DE-627)NLM255682921 
035 |a (NLM)26680606 
035 |a (PII)S1521-6616(15)30071-1 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Montanucci, Pia  |e verfasserin  |4 aut 
245 1 0 |a Restoration of t cell substes of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells  |b An in vitro study 
264 1 |c 2016 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 28.06.2016 
500 |a Date Revised 03.01.2025 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2015. Published by Elsevier Inc. 
520 |a Human umbilical cord Wharton jelly-derived mesenchymal stem cells (hUCMS) might apply to treating chronic autoimmune disorders, as already shown for Sjögren's syndrome, including type 1 diabetes mellitus (T1D). Since naked hUCMS grafts encountered restraints, we enveloped hUCMS, within immunoisolatory microcapsules (CpS-hUCMS), made of our endotoxin-free, clinical grade alginate. We then examined the vitro effects of interferon (IFN)-γ-pretreated CpS-hUCMS on Th17 and Treg of T1D patients (n=15) and healthy controls (n=10). Peripheral blood mononuclear cells (PBMCs) were co-cultured with PBMC/CpS-hUCMS: lymphocyte proliferation was assessed by carboxyfluorescein succinimidyl esther (CFSE) dilution assay, and phenotypic analysis of regulatory and effector Tc was also performed. Cytokine expression was performed by bead array and qPCR on IFN-γ-pretreated hUCMS before PBMCs co-culture. CpS-hUCMS restored a correct Treg/Th17 ratio, relevant to the T1D disease process. In summary, we have preliminarily developed a new biohybrid system, associated with immunoregulatory properties, that is ready for in vivo application 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Adult mesenchymal stem cell 
650 4 |a HLAG-5 
650 4 |a Immunomodulation 
650 4 |a Microencapsulation 
650 4 |a Proliferation inhibition 
650 4 |a Type 1 diabetes mellitus 
650 7 |a Antiviral Agents  |2 NLM 
650 7 |a Capsules  |2 NLM 
650 7 |a FOXP3 protein, human  |2 NLM 
650 7 |a Forkhead Transcription Factors  |2 NLM 
650 7 |a HLA-G Antigens  |2 NLM 
650 7 |a IDO1 protein, human  |2 NLM 
650 7 |a IL10 protein, human  |2 NLM 
650 7 |a IL17A protein, human  |2 NLM 
650 7 |a IL2 protein, human  |2 NLM 
650 7 |a IL6 protein, human  |2 NLM 
650 7 |a Indoleamine-Pyrrole 2,3,-Dioxygenase  |2 NLM 
650 7 |a Interleukin-17  |2 NLM 
650 7 |a Interleukin-2  |2 NLM 
650 7 |a Interleukin-6  |2 NLM 
650 7 |a Interleukins  |2 NLM 
650 7 |a TNF protein, human  |2 NLM 
650 7 |a Transforming Growth Factor beta  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a Interleukin-10  |2 NLM 
650 7 |a 130068-27-8  |2 NLM 
650 7 |a Interferon-gamma  |2 NLM 
650 7 |a 82115-62-6  |2 NLM 
650 7 |a NOS2 protein, human  |2 NLM 
650 7 |a EC 1.14.13.39  |2 NLM 
650 7 |a Nitric Oxide Synthase Type II  |2 NLM 
650 7 |a EC 1.14.13.39  |2 NLM 
650 7 |a Hypoxanthine Phosphoribosyltransferase  |2 NLM 
650 7 |a EC 2.4.2.8  |2 NLM 
650 7 |a Interleukin-21  |2 NLM 
650 7 |a MKM3CA6LT1  |2 NLM 
700 1 |a Alunno, Alessia  |e verfasserin  |4 aut 
700 1 |a Basta, Giuseppe  |e verfasserin  |4 aut 
700 1 |a Bistoni, Onelia  |e verfasserin  |4 aut 
700 1 |a Pescara, Teresa  |e verfasserin  |4 aut 
700 1 |a Caterbi, Sara  |e verfasserin  |4 aut 
700 1 |a Pennoni, Ilaria  |e verfasserin  |4 aut 
700 1 |a Bini, Vittorio  |e verfasserin  |4 aut 
700 1 |a Gerli, Roberto  |e verfasserin  |4 aut 
700 1 |a Calafiore, Riccardo  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 163(2016) vom: 15. Feb., Seite 34-41  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:163  |g year:2016  |g day:15  |g month:02  |g pages:34-41 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2015.12.002  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 163  |j 2016  |b 15  |c 02  |h 34-41